Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

167.26 -2.10 (-1.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
From Natera, Inc.
Via Business Wire
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Key Takeaways From Natera Analyst Ratings
Via Benzinga
How Is The Market Feeling About Natera?
Via Benzinga
Looking Into Natera's Recent Short Interest
Via Benzinga
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Natera
Via Benzinga
Looking Into Natera's Recent Short Interest
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
Via Investor Brand Network
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise
The company put up a "robust" beat and raise following an increase in test volume and sales prices in women's health and cancer detection. 
Via Investor's Business Daily
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning! 
Via InvestorPlace
US Stocks Set To End Week Strong With S&P 500 Eyeing Break Above Late-March Peak: Analyst Says He's Still A Buy In May Amid This Positive Signal
U.S. stocks are on track to finish the week on a high, with the index futures pointing to a higher opening on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024
NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Natera Reports First Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter 2024 Results on May 9
From Natera, Inc.
Via Business Wire
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
From Natera, Inc.
Via Business Wire
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
From Natera, Inc.
Via Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
From Natera, Inc.
Via Business Wire
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.